These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 18649067

  • 21. Notch Signaling Mediates Astrocyte Abnormality in Spinal Muscular Atrophy Model Systems.
    Ohuchi K, Funato M, Yoshino Y, Ando S, Inagaki S, Sato A, Kawase C, Seki J, Saito T, Nishio H, Nakamura S, Shimazawa M, Kaneko H, Hara H.
    Sci Rep; 2019 Mar 06; 9(1):3701. PubMed ID: 30842449
    [Abstract] [Full Text] [Related]

  • 22. Non-aggregating tau phosphorylation by cyclin-dependent kinase 5 contributes to motor neuron degeneration in spinal muscular atrophy.
    Miller N, Feng Z, Edens BM, Yang B, Shi H, Sze CC, Hong BT, Su SC, Cantu JA, Topczewski J, Crawford TO, Ko CP, Sumner CJ, Ma L, Ma YC.
    J Neurosci; 2015 Apr 15; 35(15):6038-50. PubMed ID: 25878277
    [Abstract] [Full Text] [Related]

  • 23. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
    Dachs E, Piedrafita L, Hereu M, Esquerda JE, Calderó J.
    Neuroscience; 2013 Oct 10; 250():417-33. PubMed ID: 23876328
    [Abstract] [Full Text] [Related]

  • 24. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
    Feng Z, Ling KK, Zhao X, Zhou C, Karp G, Welch EM, Naryshkin N, Ratni H, Chen KS, Metzger F, Paushkin S, Weetall M, Ko CP.
    Hum Mol Genet; 2016 Mar 01; 25(5):964-75. PubMed ID: 26758873
    [Abstract] [Full Text] [Related]

  • 25. The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy.
    Ahmad S, Wang Y, Shaik GM, Burghes AH, Gangwani L.
    Hum Mol Genet; 2012 Jun 15; 21(12):2745-58. PubMed ID: 22422766
    [Abstract] [Full Text] [Related]

  • 26. Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice.
    Hsu YY, Jong YJ, Tsai HH, Tseng YT, An LM, Lo YC.
    Br J Pharmacol; 2012 Jun 15; 166(3):1114-26. PubMed ID: 22220673
    [Abstract] [Full Text] [Related]

  • 27. A critical smn threshold in mice dictates onset of an intermediate spinal muscular atrophy phenotype associated with a distinct neuromuscular junction pathology.
    Bowerman M, Murray LM, Beauvais A, Pinheiro B, Kothary R.
    Neuromuscul Disord; 2012 Mar 15; 22(3):263-76. PubMed ID: 22071333
    [Abstract] [Full Text] [Related]

  • 28. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy.
    Kissel JT, Scott CB, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, LaSalle B, Prior TW, Sorenson S, Maczulski JA, Bromberg MB, Chan GM, Swoboda KJ, Project Cure Spinal Muscular Atrophy Investigators' Network.
    PLoS One; 2011 Mar 15; 6(7):e21296. PubMed ID: 21754985
    [Abstract] [Full Text] [Related]

  • 29. Motor transmission defects with sex differences in a new mouse model of mild spinal muscular atrophy.
    Deguise MO, De Repentigny Y, Tierney A, Beauvais A, Michaud J, Chehade L, Thabet M, Paul B, Reilly A, Gagnon S, Renaud JM, Kothary R.
    EBioMedicine; 2020 May 15; 55():102750. PubMed ID: 32339936
    [Abstract] [Full Text] [Related]

  • 30. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect.
    Gavrilina TO, McGovern VL, Workman E, Crawford TO, Gogliotti RG, DiDonato CJ, Monani UR, Morris GE, Burghes AH.
    Hum Mol Genet; 2008 Apr 15; 17(8):1063-75. PubMed ID: 18178576
    [Abstract] [Full Text] [Related]

  • 31. The DcpS inhibitor RG3039 improves motor function in SMA mice.
    Van Meerbeke JP, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin MY, Rucki AA, Wee CD, Xia B, Sharma S, Jacques V, Li DK, Pellizzoni L, Rusche JR, Ko CP, Sumner CJ.
    Hum Mol Genet; 2013 Oct 15; 22(20):4074-83. PubMed ID: 23727836
    [Abstract] [Full Text] [Related]

  • 32. Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts.
    Farrelly-Rosch A, Lau CL, Patil N, Turner BJ, Shabanpoor F.
    Neurochem Int; 2017 Sep 15; 108():213-221. PubMed ID: 28389270
    [Abstract] [Full Text] [Related]

  • 33. Restoring Bcl-x(L) levels benefits a mouse model of spinal muscular atrophy.
    Tsai LK, Tsai MS, Ting CH, Wang SH, Li H.
    Neurobiol Dis; 2008 Sep 15; 31(3):361-7. PubMed ID: 18590823
    [Abstract] [Full Text] [Related]

  • 34. AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice.
    Besse A, Astord S, Marais T, Roda M, Giroux B, Lejeune FX, Relaix F, Smeriglio P, Barkats M, Biferi MG.
    Mol Ther; 2020 Aug 05; 28(8):1887-1901. PubMed ID: 32470325
    [Abstract] [Full Text] [Related]

  • 35. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
    Cobb MS, Rose FF, Rindt H, Glascock JJ, Shababi M, Miller MR, Osman EY, Yen PF, Garcia ML, Martin BR, Wetz MJ, Mazzasette C, Feng Z, Ko CP, Lorson CL.
    Hum Mol Genet; 2013 May 01; 22(9):1843-55. PubMed ID: 23390132
    [Abstract] [Full Text] [Related]

  • 36. Decreased Motor Neuron Support by SMA Astrocytes due to Diminished MCP1 Secretion.
    Martin JE, Nguyen TT, Grunseich C, Nofziger JH, Lee PR, Fields D, Fischbeck KH, Foran E.
    J Neurosci; 2017 May 24; 37(21):5309-5318. PubMed ID: 28450545
    [Abstract] [Full Text] [Related]

  • 37. Activation of Muscle-Specific Kinase (MuSK) Reduces Neuromuscular Defects in the Delta7 Mouse Model of Spinal Muscular Atrophy (SMA).
    Feng Z, Lam S, Tenn ES, Ghosh AS, Cantor S, Zhang W, Yen PF, Chen KS, Burden S, Paushkin S, Ayalon G, Ko CP.
    Int J Mol Sci; 2021 Jul 27; 22(15):. PubMed ID: 34360794
    [Abstract] [Full Text] [Related]

  • 38. Restoration of SMN in Schwann cells reverses myelination defects and improves neuromuscular function in spinal muscular atrophy.
    Hunter G, Powis RA, Jones RA, Groen EJ, Shorrock HK, Lane FM, Zheng Y, Sherman DL, Brophy PJ, Gillingwater TH.
    Hum Mol Genet; 2016 Jul 01; 25(13):2853-2861. PubMed ID: 27170316
    [Abstract] [Full Text] [Related]

  • 39. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy.
    Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, Keyvan M, Pai G, Mishra R, Haraldsson M, Andresson T, Bragason G, Thosteinsdottir M, Bjornsson JM, Coovert DD, Burghes AH, Gurney ME, Singh J.
    J Med Chem; 2008 Feb 14; 51(3):449-69. PubMed ID: 18205293
    [Abstract] [Full Text] [Related]

  • 40. In vivo NMDA receptor activation accelerates motor unit maturation, protects spinal motor neurons, and enhances SMN2 gene expression in severe spinal muscular atrophy mice.
    Biondi O, Branchu J, Sanchez G, Lancelin C, Deforges S, Lopes P, Pariset C, Lécolle S, Côté J, Chanoine C, Charbonnier F.
    J Neurosci; 2010 Aug 25; 30(34):11288-99. PubMed ID: 20739549
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.